Dimitris Spyridakos

Mr. Dimitris Spyridakos

University of Crete, Heraklion, Greece
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DSDimitris Spyridakos
Dimitris Spyridakos
NMNiki Mastrodimou
Niki Mastrodimou
KVKiran Vemuri
Kiran Vemuri
THThanh Ho
Thanh Ho
Spyros NikasSpyros Nikas
Spyros Nikas
KTKyriaki Thermos
Kyriaki Thermos
Oxidative stress, neurodegeneration, neuroinflammation, and vascular leakage are believed to play a key role in the early stage of diabetic retinopathy (ESDR). The aim of this study was to investigate the blockade of cannabinoid receptor 1 (CB1R) and activation of cannabinoid receptor 2 (CB2R) as putative therapeutics for the treatment of the early toxic events in DR. Diabetic rats [streptozotocin (STZ)-induced] were treated topically (20 μL, 10 mg/mL), once daily for fourteen days (early stage DR model), with SR141716 (CB1R antagonist), AM1710 (CB2R agonist), and the dual treatment SR141716/AM1710. Immunohistochemical-histological, ELISA, and Evans-Blue analyses were performed to assess the neuroprotective and vasculoprotective properties of the pharmacological treatments on diabetes-induced retinal toxicity. Activation of CB2R or blockade of CB1R, as well as the dual treatment, attenuated the nitrative stress induced by diabetes. Both single treatments protected neural elements (e.g., RGC axons) and reduced vascular leakage. AM1710 alone reversed all toxic insults. These findings provide new knowledge regarding the differential efficacies of the cannabinoids, when administered topically, in the treatment of ESDR. Cannabinoid neuroprotection of the diabetic retina in ESDR may prove therapeutic in delaying the development of the advanced stage of the disease.

Verified
Journal Article
Open access
PDF file
SPSofia PAPADOGKONAKI
Sofia PAPADOGKONAKI
DSDimitris Spyridakos
Dimitris Spyridakos
ELEmmanouela Lapokonstantaki
Emmanouela Lapokonstantaki
Nikos ChaniotakisNikos Chaniotakis
Nikos Chaniotakis
AMAlexandros Makriyannis
Alexandros Makriyannis
KTKyriaki Thermos
Kyriaki Thermos
The endocannabinoid system (ECS) is a new target for the development of retinal disease therapeutics, whose pathophysiology involves neurodegeneration and neuroinflammation. The endocannabinoid 2-arachidonoylglycerol (2-AG) affects neurons and microglia by activating CB1/CB2 cannabinoid receptors (Rs). The aim of this study was to investigate the effects of 2-AG on the CB1R expression/downregulation and retinal neurons/reactive microglia, when administered repeatedly (4 d), in three different paradigms. These involved the 2-AG exogenous administration (a) intraperitoneally (i.p.) and (b) topically and (c) by enhancing the 2-AG endogenous levels via the inhibition (AM11920, i.p.) of its metabolic enzymes (MAGL/ABHD6). Sprague Dawley rats were treated as mentioned above in the presence or absence of CB1/CB2R antagonists and the excitatory amino acid, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA). Immunohistochemistry, Western blot and a 2-AG level analyses were performed. The 2-AG repeated treatment (i.p.) induced the CB1R downregulation, abolishing its neuroprotective actions. However, 2-AG attenuated the AMPA-induced activation of microglia via the CB2R, as concurred by the AM630 antagonist effect. Topically administered 2-AG was efficacious as a neuroprotectant/antiapoptotic and anti-inflammatory agent. AM11920 increased the 2-AG levels providing neuroprotection against excitotoxicity and reduced microglial activation without affecting the CB1R expression. Our findings show that 2-AG, in the three paradigms studied, displays differential pharmacological profiles in terms of the downregulation of the CB1R and neuroprotection. All treatments, however, attenuated the activation of microglia via the CB2R activation, supporting the anti-inflammatory role of 2-AG in the retina.

14 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
DSDimitris Spyridakos
Dimitris Spyridakos
IZIoannis Zyganitidis
Ioannis Zyganitidis
SPSofia Petsangouraki
Sofia Petsangouraki
CKChrystalla Konstantinou
Chrystalla Konstantinou
ATAlexandros Tsimpolis
Alexandros Tsimpolis
 Domna  Karagogeos Domna Karagogeos
Domna Karagogeos
Excitotoxicity mediated by the α-amino-3-hydroxy-5-methyl-4 isoxazolepropionic acid receptor (AMPAR) is a major contributor to neuronal degeneration and inflammation in various neurological disorders. The endocannabinoid system (ECS), specifically through the endocannabinoid 2-arachidonoylglycerol (2-AG), exerts neuroprotective and anti-inflammatory effects, but these actions are limited by enzymatic degradation of 2-AG by monoacylglycerol lipase (MAGL) and α/β-hydrolase domain-containing protein 6 (ABHD6). In the present study we investigated the effects of AM11920, a dual MAGL/ABHD6 inhibitor, in a mouse model of AMPA-induced cortical excitotoxicity and in primary cultures of microglia, neurons, and oligodendrocyte precursor cells (OPCs). Intraperitoneal administration (i.p.) of AM11920 reduced microglial and astrocytic reactivity, attenuated neuronal loss, and increased the density of mature oligodendrocytes at the lesion site in vivo. Importantly, chronic administration of AM11920 in vivo did not affect cannabinoid receptor type 1 (CB1R) protein expression. In vitro, AM11920 suppressed microglial activation by reducing CD68 expression and attenuated interleukin-6 (IL-6) expression, while also protecting primary neurons and OPCs from AMPA-induced cell death via a CB1R-dependent mechanism. Collectively, these findings demonstrate that enhancing 2-AG signaling through dual MAGL/ABHD6 blockade provides neuroprotective and immunomodulatory effects and represents a promising therapeutic strategy against excitotoxic-induced neurodegeneration.